|
Post by seanismorris on Feb 28, 2016 18:33:42 GMT -5
I don't have an exit price, it all depends on what MannKind is doing... I may trade MNKD.
I will say that if MannKind split into to companies today, I'd sell the Afrezza shares and double down on TS.
Afrezza has been a disaster but Management has learned a lot. I bet if MannKind went back in time they would have avoided insulin and created more of a strategy that they are pursuing today (which regards to the TS formulations under development).
Afrezza really needs more and better designed clinical trials showing superiority to be a complete success. I'm not sure it's worth the cash and may have been a poor starting point for the technology.
|
|
|
Post by falconquest on Feb 28, 2016 21:47:57 GMT -5
I don't have an exit price, it all depends on what MannKind is doing... I may trade MNKD. I will say that if MannKind split into to companies today, I'd sell the Afrezza shares and double down on TS. Afrezza has been a disaster but Management has learned a lot. I bet if MannKind went back in time they would have avoided insulin and created more of a strategy that they are pursuing today (which regards to the TS formulations under development). Afrezza really needs more and better designed clinical trials showing superiority to be a complete success. I'm not sure it's worth the cash and may have been a poor starting point for the technology. Please keep in mind that Mannkind followed the FDA testing guidelines to a "T" following the second CRL. It certainly wasn't the design they could have conducted.
|
|
|
Post by patten1962 on Feb 29, 2016 6:43:11 GMT -5
I don't have an exit price, it all depends on what MannKind is doing... I may trade MNKD. I will say that if MannKind split into to companies today, I'd sell the Afrezza shares and double down on TS. Afrezza has been a disaster but Management has learned a lot. I bet if MannKind went back in time they would have avoided insulin and created more of a strategy that they are pursuing today (which regards to the TS formulations under development). Afrezza really needs more and better designed clinical trials showing superiority to be a complete success. I'm not sure it's worth the cash and may have been a poor starting point for the technology. I would respectfully disagree about Affrezza being a disaster. Sanofi was the disaster!
|
|
|
Post by lorcan458 on Feb 29, 2016 9:55:59 GMT -5
Based on the medical results of Afrezza, plus technosphere, the patent library...$22.
|
|
|
Post by miracle331 on Feb 29, 2016 12:18:57 GMT -5
my current avg is $4.21, I'd get out @ $5 just to get this over with. However, depending on the situation of the company, might buy back in.
|
|
|
Post by patten1962 on Feb 29, 2016 18:07:15 GMT -5
my current avg is $4.21, I'd get out @ $5 just to get this over with. However, depending on the situation of the company, might buy back in. Would any of you stay in and protect your investment with puts?
|
|
|
Post by bioexec25 on Feb 29, 2016 18:38:03 GMT -5
Patten, is your proboard name after Gen George S Patten's son who's first of three Vietnam tours started in 1962?
Just noticed the date, maybe unrelated. :-))
|
|
|
Post by patten1962 on Feb 29, 2016 22:06:31 GMT -5
Patten, is your proboard name after Gen George S Patten's son who's first of three Vietnam tours started in 1962? Just noticed the date, maybe unrelated. :-)) No. My real name is Patten. Born in 1962. .
|
|
|
Post by me on Mar 1, 2016 10:37:17 GMT -5
General "Patton"
|
|